The Inspectorate and Enforcement Directorate within the Medicines Authority has said that Janssen-Cilag International N.V. are initiating a voluntary preventative product recall of Cilest® 250/35 Oral Contraceptive Tablets (250µg norgestimate 35µg ethinyl estradiol).

The recall of Cilest® is being affected due to a reported slower than expected solubility of an active ingredient. This can potentially lead to decreased contraceptive effect. It has been reported that the likelihood of patients experiencing an adverse event due to this appears to be very low.

Stock of Cilest® will be withdrawn from pharmacies.

Patients are requested to contact their doctor to be advised regarding the continuation of their treatment.

For more information, please phone on 2343 9000.

Permalink: Medicines recall Cilest® 250/35 Oral Contraceptive tablets